FDA drug reviewers advise against Lilly's amyloid imaging agent
This article was originally published in Scrip
Executive Summary
Ahead of a meeting of the US FDA's Peripheral and Central Nervous System Drugs Advisory Committee, agency drug reviewers 18 January recommended against approval of Lilly's Amyvid (florbetapir F 18), stating that data in the firm's new drug application failed to confirm the investigational radiopharmaceutical's efficacy in detecting beta amyloid in the brain during positron emission tomography (PET) imaging.